LeanTaaS is a software company that uses lean principles, machine learning, and predictive analytics to digitally transform core operational processes in healthcare. This transformation increases patient access, decreases wait times, improves staff satisfaction, reduces healthcare delivery costs, and improves operational performance. LeanTaaS's cloud-based iQueue platform mathematically matches the demand for expensive, constrained healthcare resources – operating rooms, infusion chairs, imaging assets, inpatient beds, etc.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

news image

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More

INDUSTRIAL IMPACT

ILLUMINA LAUNCHES STRATEGIC RESEARCH COLLABORATION WITH ASTRAZENECA TO ACCELERATE DRUG TARGET DISCOVERY

Illumina, Inc. | October 12, 2022

news image

Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence o...

Read More

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

news image

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More

CONCERTAI CREATES COVID-19 RESOURCES FOR ONCOLOGY TO SUPPORT HEALTHCARE PROVIDERS, BIOPHARMACEUTICAL INNOVATORS, AND BIOMEDICAL RESEARCHERS

ConcertAI | October 08, 2020

news image

ConcertAI has launched a set of COVID-19 resources for oncology to support the needs of healthcare providers, biopharmaceutical innovators, and biomedical researchers as they look to maintain patient access to new and critical treatments and improve outcomes during this pandemic. Abstracted sets of aggregated, de-identified real-world data (RWD) will be derived from CancerLinQ Discovery™– a project of CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clin...

Read More
news image

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More
news image

INDUSTRIAL IMPACT

ILLUMINA LAUNCHES STRATEGIC RESEARCH COLLABORATION WITH ASTRAZENECA TO ACCELERATE DRUG TARGET DISCOVERY

Illumina, Inc. | October 12, 2022

Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence o...

Read More
news image

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More
news image

CONCERTAI CREATES COVID-19 RESOURCES FOR ONCOLOGY TO SUPPORT HEALTHCARE PROVIDERS, BIOPHARMACEUTICAL INNOVATORS, AND BIOMEDICAL RESEARCHERS

ConcertAI | October 08, 2020

ConcertAI has launched a set of COVID-19 resources for oncology to support the needs of healthcare providers, biopharmaceutical innovators, and biomedical researchers as they look to maintain patient access to new and critical treatments and improve outcomes during this pandemic. Abstracted sets of aggregated, de-identified real-world data (RWD) will be derived from CancerLinQ Discovery™– a project of CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clin...

Read More